Cost-Effectiveness of Atidarsagene Autotemcel (ARSA-CEL) Gene Therapy for Treating Metachromatic Leukodystrophy (MLD) in Ireland, Belgium, and the Netherlands As a Part of the Beneluxa Initiative

Author(s)

Olaye A1, Bean K2, Velikanova R3, Wolters S3, Miller B4, Jensen I4, Pang F5
1Orchard Therapeutics, London, UK, 2Orchard Therapeutics, Hook, HAM, UK, 3Asc Academics, Groningen, GR, Netherlands, 4Precision AQ, Boston, MA, USA, 5Orchard Therapeutics, London, LON, UK

OBJECTIVES: MLD is an ultra-rare, inherited, multi-systemic disease, with aggressive forms manifesting early in late-infantile and early juvenile stages, which lead to rapid physical and cognitive decline, resulting in significant loss of quality of life (QoL) and premature death. Currently, no approved treatment exists for early-onset MLD. Consequently, the standard of care consists primarily of the best supportive care in Ireland, Belgium, and the Netherlands. This study evaluates the cost-effectiveness of arsa-cel, a one-time gene therapy, compared to BSC.

METHODS: The cost-effectiveness analysis employs a seven-state partitioned survival model, with a monthly cycle length and lifetime horizon, conducted from a healthcare payer perspective for Ireland and Belgium and a societal perspective for the Netherlands. Transition probabilities were informed by clinical trial data, published literature, national registry data, and expert opinions. Discount rates and costs specific to each country were applied in the analysis. Utilities were derived from a study using vignette and time trade-off methods and were subsequently rescaled to align with national tariff standards to reflect the preferences of each country.

RESULTS: For the combined MLD population, the base case ICERs for arsa-cel versus BSC were €146,642 in Ireland, €118,234 in Belgium, and €107,777 in the Netherlands, with incremental QALY gains of 15.5, 25.5, and 24.6, respectively. In a scenario analysis that included a societal perspective (including lost family income, out-of-pocket costs, and productivity gains using the Human Capital Approach), newborn screening, and caregiver disutility, the ICERs for arsa-cel versus BSC were €45,574 for Ireland, €40,374 for Belgium, and €38,803 for the Netherlands.

CONCLUSIONS: Findings suggest arsa-cel yields lifelong QoL improvements, with variable cost-effectiveness among countries due to differing modelling requirements and inputs. Scenario analyses reveal that including broader considerations, such as the societal perspective, newborn screening, and impact on caregivers, considerably lowers all the ICERs, underscoring arsa-cel's value.

Conference/Value in Health Info

2024-11, ISPOR Europe 2024, Barcelona, Spain

Value in Health, Volume 27, Issue 12, S2 (December 2024)

Code

EE693

Topic

Economic Evaluation

Topic Subcategory

Cost-comparison, Effectiveness, Utility, Benefit Analysis

Disease

Genetic, Regenerative & Curative Therapies, Pediatrics, Rare & Orphan Diseases

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×